Breaking News

Scientists have just discovered that an antibody from a patient with a severe acute respiratory syndrome (SARS) could be used to develop a drug to treat COVID-19.



According to the South China Morning Post, the study was conducted by the University of Washington, Seattle (USA), the National Institute of Medical Sciences and the National Institute of Allergy & Infectious Diseases, published on May 18.

Research results show that antibodies called S309 have the ability to bind and disable the spikes protein helps the virus attach to the host cell.

As explained by David Veesler, assistant professor of biochemistry, one of the lead authors of the study, the prickly proteins "pave the way" for viruses to invade cells. They are also the main target of neutralizing antibodies (in the immune system) that protect the body from infection.
Analysis of the scientists showed that the S309 antibody binds to the prickly protein of all corona virus, not just SARS or nCoV.

As such, it can be used alone or in combination with S309 to treat COVID-19 patients or to prevent those susceptible to viral infections such as frontline health care workers.

However, the scientists noted that the study was done only in the laboratory, needing to dig deeper to know S309's ability to resist human nCoV. If effective, they will use it to develop the drug COVID-19.

Meanwhile, two "candidates" of the drug refined from antibodies S309 will be clinically tested by Vir Biotechnology Company, based in California (USA) this summer.

There is currently no official treatment for COVID-19. Global scientists and pharmacies are working to develop effective and safe medicines to fight the disease.

No comments